close

Fundraisings and IPOs

Date: 2018-04-19

Type of information: Series A financing round

Company: Tmunity Therapeutics (USA - PA)

Investors: Kleiner Perkins (USA) Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences, (USA - CA) Be The Match BioTherapies (USA - MN) University of Pennsylvania (USA - PA) Lilly Asia Ventures (China)

Amount: $135 million

Funding type: series A financing round

Planned used:

  • Tmunity Therapeutics was founded on an exclusive collaboration and license agreement with the University of Pennsylvania, offering proprietary technologies and the unparalleled expertise in first-in-patient cell and gene therapies of its scientific founders, led by Carl H. June, MD. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body.
  • The proceeds from the Series A will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer.
 

Others:

  • • On April 19, 2018, Tmunity Therapeutics announced an additional $35 million Series A investment from Kleiner Perkins and affiliates. This investment brings the total Tmunity Series A financing to $135 million.
  • • On January 23, 2018, Tmunity Therapeutics announced the closing of a $100 million Series A financing. Syndicate investors, which include Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences and Be The Match BioTherapies, join seed round investors, the University of Pennsylvania and Lilly Asia Ventures.
   

Therapeutic area: Cancer - Oncology

Is general: Yes